NEWS
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Just Updated: Compare Your Institution (Live Data)
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025 (Updated Today)
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
For Students
local_fire_department
Country Reports
person
Find a Professional
Akram Khan
i
Oregon Health & Science University - Portland / United States
Medical and Health Sciences / Health Sciences
AD Scientific Index ID: 885885
Registration, Add Profile,
Premium Membership
Get Your Global Impact Certificate
Ranking &
Analysis
Job
Experiences
Education
Information
Published Books
Book Chapters
Articles
Presentations
Lessons
Projects
Co-Authors
Subject Leaders
Editorship, Referee &
Scientific Board
Patents /
Designs
Academic Grants
& Awards
Artistic
Activities
Certificate / Course
/ Trainings
Association &
Society Memberships
Contact, Office
& Social Media
person_outline
Akram Khan's MOST POPULAR ARTICLES
1-)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017
2-)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Lancet (London, England) 397 (10285), 1637, 2021
3-)
Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020 MMWR. Morbidity and mortality weekly report 69, 2020
4-)
Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19 New England Journal of Medicine 385 (9), 790-802, 2021
5-)
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial The Lancet 399 (10325), 665-676, 2022
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept